Industry News

Pharmaceutical Industry News

As part of the MFN drug pricing…

September 2nd, 2026|Fierce Pharma|

As part of the MFN drug pricing deal the Trump administration signed with obesity giants Eli Lilly and Novo Nordisk, Medicare recently launched a “bridge” model, offering weight loss drugs to eligible seniors at $50

TV outcomes company EDO determined…

September 1st, 2026|Fierce Pharma|

TV outcomes company EDO determined that Galderma’s skin disease med Nemluvio led the charge with the highest engagement score across all advertisers during the 2025-26 NFL football season.

After pivoting from mobile gaming…

September 1st, 2026|Fierce Pharma|

After pivoting from mobile gaming marketing to pharma, Genentech performance marketing engagement lead Tiffany William is making performance marketing "less daunting" and "more fun" and approachable.

Novartis appears to have broken…

September 1st, 2026|Fierce Pharma|

Novartis appears to have broken the curse of the BTK inhibitor class. The Swiss pharma announced Tuesday that two phase 3 trials for Rhapsido in relapsing multiple sclerosis hit their goals without any liver safety

This podcast feature a fireside…

September 1st, 2026|Fierce Pharma|

This podcast feature a fireside chat between Dr Ira Mellman, PICI and Dr Axel Hoos, Former CEO, Scorpion Therapeutics from the 2026 Immuno-Oncology 360° conference.

A new survey out from Bausch +…

September 1st, 2026|Fierce Pharma|

A new survey out from Bausch + Lomb has shown that dry eye disease is one of the least recognized symptoms present in perimenopausal and postmenopausal women.

Emergent BioSolutions looks to…

August 31st, 2026|Fierce Pharma|

Emergent BioSolutions looks to expand awareness and education of its Narcan opioid overdose reversal spray with an expanded campaign that kicked off on International Overdose Awareness Day.

Some four months after the White…

August 31st, 2026|Fierce Pharma|

Some four months after the White House inked the last of its expected drug pricing deals with 17 of the industry’s top players, the U.S. government is back for round 2, this time lining up

BioMarin now collects royalties on…

August 31st, 2026|Fierce Pharma|

BioMarin now collects royalties on the more convenient competitor product. Ascendis will pay 20% of Yuviwel net sales in the U.S. dating back to the first commercial sales and through to May 2030.

Samanta Cimitan, Ph.D., will serve…

August 31st, 2026|Fierce Pharma|

Samanta Cimitan, Ph.D., will serve in a newly created role as the CDMO's chief commercial officer, SVP and member of the extended executive committee starting Jan. 1, 2027.

Jazz Pharmaceuticals has added a…

August 31st, 2026|Fierce Pharma|

Jazz Pharmaceuticals has added a second overall survival win to Ziihera’s cap, bolstering the bispecific’s claim as the new HER2 agent of choice in stomach cancer.

Late August has been rough for IV…

August 31st, 2026|Fierce Pharma|

Late August has been rough for IV solution makers as B. Braun added to its recall tally once more, building on Baxter’s three recalls of similar products in the same time frame.

After a surprise washout in a…

August 29th, 2026|Fierce Pharma|

After a surprise washout in a recent phase 3 trial of AstraZeneca and Ionis’ antisense oligonucleotide Wainua, the likely reason for the miss is being laid bare, in a potential ill omen for others pursuing

The FDA has approved Takeda’s…

August 28th, 2026|Fierce Pharma|

The FDA has approved Takeda’s Mimrylo (rusfertide) for polycythemia vera, introducing a new mechanism to the nonmalignant rare blood cancer and handing CEO Julie Kim another major regulatory win since taking the helm.

The FDA has signed off on a label…

August 28th, 2026|Fierce Pharma|

The FDA has signed off on a label expansion for PharmaEssentia's Besremi, endorsing it as a treatment for the rare bone marrow disorder essential thrombocythemia.